Patents Assigned to Universitatsmedizin der Johannes Gutenberg-Universitat Mainz
-
Patent number: 10117918Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: GrantFiled: December 28, 2016Date of Patent: November 6, 2018Assignees: BioNTech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbhInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Patent number: 10093736Abstract: The present invention provides binding agents that contain a binding domain that is specific for CD3 allowing binding to T cells and a binding domain that is specific for a tumor-associated claudin molecule and methods of using these binding agents or nucleic acids encoding therefor for treating cancer.Type: GrantFiled: November 12, 2013Date of Patent: October 9, 2018Assignees: BIONTECH AG, TRON GGMBH, UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ, GANYMED PHARMACEUTICALS AGInventors: Ugur Sahin, Ozlem Tureci, Christiane Stadler, Julia Holland, Hayat Bahr-Mahmud, Tim Beissert, Laura Plum, Fabrice Le Gall, Arne Jendretzki, Markus Fiedler
-
Patent number: 10059996Abstract: The present invention relates to a method for predicting the non-response or response to a monoaminergic antidepressant of a patient to be treated with a monoaminergic antidepressant comprising the steps: (i) determining the DNA-methylation status of a brain-derived neurotrophic factor (BDNF)-gene promoter in a sample of said patient; (ii) attributing a hypomethylation of said BDNF-gene promoter to the non-response to a monoaminergic antidepressant of said patient; and (iii) attributing normal methylation or hypermethylation of said BDNF-gene promoter to the response to a monoaminergic antidepressant of said patient. Furthermore, a kit and the use of a kit in said method is disclosed.Type: GrantFiled: May 8, 2013Date of Patent: August 28, 2018Assignees: Medizineische Hochschule Hannover, Universitätsmedizin der Johannes-Gutenberg-Universität MainzInventors: Helge Frieling, André Tadic, Stefan Bleich, Klaus J. Lieb
-
Patent number: 10022444Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: August 8, 2016Date of Patent: July 17, 2018Assignees: GANYMED PHARMACEUTICALS AG, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITAT MAINZ GEMEINNUTZIGE GMBHInventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
-
Patent number: 9950065Abstract: The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.Type: GrantFiled: September 26, 2013Date of Patent: April 24, 2018Assignees: BIONTECH RNA PHARMACEUTICALS GMBH, TRON—TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUZIGE GMBHInventors: Ugur Sahin, Heinrich Haas, Sebastian Kreiter, Yves Hüsemann, Mustafa Diken, Kerstin Reuter, Hossam Hefresha
-
Patent number: 9770487Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as pancreatic cancer and metastases thereof.Type: GrantFiled: February 18, 2014Date of Patent: September 26, 2017Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gGmbHInventors: Ugur Sahin, Ozlem Tureci, Rita Mitnacht-Kraus, Stefan Woll, Stefan Jacobs, Cornelia Heinz
-
Patent number: 9624292Abstract: The present invention relates to a single chain antigen recognizing construct (scARC), which is composed of stabilized variable domains by the introduction of novel disulfide bonds, in order to prevent residual mis-pairing with endogenous ARC chains. The invention further discloses a method for the design of a novel structurally stabilized scARC, the method being based on the visual inspection of the crystal structure of the underlying scARC and the selection of appropriate amino acid substitutions to generate a novel disulfide bond in the protein structure. Furthermore, the invention discloses a method for the production of a cell which expresses the scARC of the invention. Also described are nucleic acids encoding an inventive scARC, as well as DNA and RNA constructs that allow for the expression of the inventive scARC.Type: GrantFiled: March 26, 2012Date of Patent: April 18, 2017Assignee: Universitätsmedizin Der Johannes Gutenberg-Universität MainzInventors: Ralf-Holger Voss, Shao-An Xue, Matthias Theobald, Hans Stauss
-
Patent number: 9586997Abstract: The present invention relates to efficient methods for providing antigen-specific lymphoid cells. These lymphoid cells may be used to provide antigen specific T cell receptors having a defined MHC restriction and to identify immunologically relevant T cell epitopes. Furthermore, the present invention relates to antigen-specific T cell receptors and T cell epitopes and their use in immunotherapy.Type: GrantFiled: September 19, 2011Date of Patent: March 7, 2017Assignees: BioNtech Cell & Gene Therapies GmbH, Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz gemeinnutzige GmbHInventors: Ugur Sahin, Ozlem Tureci, Petra Simon, Tana Omokoko
-
Patent number: 9512232Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.Type: GrantFiled: May 6, 2013Date of Patent: December 6, 2016Assignees: GANYMED PHARMACEUTICALS AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbHInventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
-
Patent number: 9433675Abstract: The present invention provides a combination therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN18.2, including cancer diseases such as gastric cancer, esophageal cancer, pancreatic cancer, lung cancer, ovarian cancer, colon cancer, hepatic cancer, head-neck cancer, and cancer of the gallbladder and metastases thereof.Type: GrantFiled: May 21, 2013Date of Patent: September 6, 2016Assignees: Ganymed Pharmaceuticals AG, TRON—Translationale Onkologie an der Universitatsmedizin der Johannes Gutenberg-Universitat Mainz Gemeinnutzige GmbHInventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Denis Jacobs, Magdalena Jadwiga Utsch, Cornelia Adriana Maria Heinz, Christiane Regina Stadler
-
Patent number: 9364459Abstract: The present invention relates to the use of a compound of formula (I) wherein R1 and R3 are as defined in the description and R2 is a phenyl group which is substituted with 2 or 3 C1-C6 alkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma.Type: GrantFiled: December 10, 2010Date of Patent: June 14, 2016Assignees: Johannes Gutenberg-Universität Mainz, Universitätsmedizin der Johannes Gutenberg-Universität MainzInventors: Gerd Dannhardt, Stanislav Plutizki, Jan-Peter Kramb, Annett Müller, Markus Möhler
-
Patent number: 9339633Abstract: The present invention relates to a balloon catheter system for draining and/or supplying fluid from/into hollow organs, body cavities or cysts, comprising a conduit catheter with an open distal end, a hollow needle guided in a separate guide conduit and a balloon surrounding the catheter stem at the distal end of the conduit catheter. The conduit catheter with the hollow needle can be inserted from outside into the hollow organ via a guide catheter, into the body cavity or cyst, the balloon can be filled with filling medium via the hollow needle through an opening formed in the guided duct and provided in the lumen of the balloon, and it can be fixed in the hollow organ, body cavity or cyst. The hollow needle can be removed from the guide duct after filling the balloon. The balloon and the conduit catheter remain in the hollow organ, body cavity or cyst.Type: GrantFiled: June 8, 2011Date of Patent: May 17, 2016Assignee: Universitatsmedizin der Johannes Gutenberg Universitat MainzInventor: Michael Tchirikov
-
Patent number: 9295717Abstract: The present invention relates to modification of RNA with 5?-cap analogs of Formula (1): wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.Type: GrantFiled: August 3, 2010Date of Patent: March 29, 2016Assignees: BIONTECH AG, TRON-TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITATSMEDIZIN DER JOHANNES GUTENBERG-UNIVERSITAT MAINZ GEMEINNUTZIGE GMBH, UNIWERSYTET WARSZAWSKIInventors: Ugur Sahin, Andreas Kuhn, Edward Darzynkiewicz, Jacek Jemielity, Joanna Kowalska
-
Patent number: 9295457Abstract: The present invention relates to a balloon catheter system for sealing puncture points or openings in body cavities, hollow organs or in percutaneous drainage operations in mammals, consisting of a filling catheter on the distal end of which a first balloon can be filled with the filling medium is arranged with a further balloon arranged proximally spaced apart therefrom. The balloons close the puncture point or the opening on the two sides in the filled state of the balloon. A hollow needle open at the shaft or the shaft end can be guided in the lumen of the filling catheter for filling the two balloons with the filling medium, wherein the shells of the two balloons enclose the shaft of the filling catheter. The filling catheter in each case has an opening arranged in the balloon lumen to fill the two balloons.Type: GrantFiled: April 20, 2011Date of Patent: March 29, 2016Assignee: Universitätsmedizin der Johannes Gutenberg Universität MainzInventor: Michael Tchirikov
-
Patent number: 9139639Abstract: The present invention provides recombinant proteins comprising the amino acid sequence of an intracellular segment of CD40 and an amino acid sequence mediating the association of the recombinant protein with the constant region of an immunoglobulin heavy chain. The recombinant proteins according to the present invention are—useful for inducing clonal expansion of a B cell having a predetermined antigen-specificity without the need for T cell or CD40L mediated co-stimulation. Thus, the present invention provides tools for clonal expansion of B cells specific for an antigen of interest and the production of B cells secreting antibodies specific for an antigen of interest. The recombinant proteins of the present invention may also be used for generating fully human monoclonal antibodies with a predetermined antigen-specificity from the B cell repertoire of a human subject.Type: GrantFiled: December 16, 2014Date of Patent: September 22, 2015Assignees: BioNTech AG, Universitatsmedizin Der Johannes Gutenberg-Universitat MainzInventors: Ugur Sahin, Ozlem Tureci, Torsten Seppmann, Holger Hoff, Jens Schumacher
-
Publication number: 20140030808Abstract: The present invention relates to enhancing RNA expression in a cell such as a cell transfected with RNA by reducing the activity of RNA-dependent protein kinase (PKR). Thus, the present invention provides methods for expressing RNA in a cell comprising the step of reducing the activity of RNA-dependent protein kinase (PKR) in the cell. Reducing the activity of RNA-dependent protein kinase (PKR) in the cell increases the stability of RNA and/or increases the expression of RNA in the cell.Type: ApplicationFiled: December 2, 2011Publication date: January 30, 2014Applicants: BIONTECH AG, Universitatsmedizin der Johannes Gutenberg- Universitat Mainz, Translationale Onkologie an der Universitatsmediz- in der JGU Mainz gGmbH (TRON)Inventors: Ugur Sahin, Tim Beissert, Marco Poleganov, Stephanie Herz
-
Publication number: 20130123622Abstract: The present invention relates to a balloon catheter system for draining and/or supplying fluid from/into hollow organs, body cavities or cysts, comprising a conduit catheter with an open distal end, a hollow needle guided in a separate guide conduit and a balloon surrounding the catheter stem at the distal end of the conduit catheter. The conduit catheter with the hollow needle can be inserted from outside into the hollow organ via a guide catheter, into the body cavity or cyst, the balloon can be filled with filling medium via the hollow needle through an opening formed in the guided duct and provided in the lumen of the balloon, and it can be fixed in the hollow organ, body cavity or cyst. The hollow needle can be removed from the guide duct after filling the balloon. The balloon and the conduit catheter remain in the hollow organ, body cavity or cyst.Type: ApplicationFiled: June 8, 2011Publication date: May 16, 2013Applicant: Universitätsmedizin der Johannes Gutenberg Universität MainzInventor: Michael Tchirikov
-
Publication number: 20130029986Abstract: The present invention relates to the use of a compound of formula (I) wherein R1 and R3 are as defined in the description and R2 is a phenyl group which is substituted with 2 or 3 C1-C6 alkoxy groups, or a physiologically acceptable salt thereof, or a solvate of the compound of formula (I) or of the salt thereof, for treatment of colorectal or gastric adenocarcinoma.Type: ApplicationFiled: December 10, 2010Publication date: January 31, 2013Applicants: Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Johannes Gutenberg-Universitat MainzInventors: Gerd Dannhardt, Stanislav Plutizki, Jan-Peter Kramb, Annett Müller, Markus Möhler